Connect with us

Investment

Chi-Med Announces US$100 Million Equity Investment by CPP Investments

Published

 on

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 17, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (Nasdaq/AIM: HCM) today announces that it has entered into a definitive agreement for the sale of US$100 million of shares at a price equivalent to US$30 per American Depositary Share (“ADS”) via a private placement to Canada Pension Plan Investment Board (“CPP Investments”).

Mr. Christian Hogg, Chief Executive Officer of Chi-Med, said, “We are very pleased to welcome CPP Investments as a shareholder. CPP Investments’ focus on building long-term value and its experience in healthcare investing make it an important global strategic partner to Chi-Med. We look forward to building on the partnership as we work, during the next six months, to launch both surufatinib and savolitinib in China, subject to approval, as well as submit our first U.S. NDA on surufatinib.”

Mr. Agus Tandiono, Managing Director and Head of Fundamental Equities Asia at CPP Investments, said, “This placement aligns with CPP Investments’ focus on providing strategic, long-term capital to industry leading companies where we can participate in the future success of the business and help create greater value through ongoing partnership. We look forward to supporting Chi-Med’s work on innovation in oncology treatment.”

Chi-Med will receive all proceeds from this private placement of the equivalent of 3,333,334 ADSs, which will fund ongoing research and clinical development and support the further growth of its commercialization capabilities both in China and globally.

Description of Share Capital and Securities Regulation

Chi-Med has agreed to issue 16,666,670 ordinary shares, par value US$0.10 each (the “Shares”), pursuant to the private placement. The Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of Chi-Med. Each ADS represents five Shares.

The securities to be sold in the private placement will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Subject to certain conditions, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the Shares sold in the private placement to facilitate future resales by CPP Investments. Any offering of the securities under the resale registration statement will only be made by means of a prospectus. CPP Investments has the right to appoint an observer and a representative director to the board of directors of the Company upon achieving certain ownership thresholds in the future.

This announcement, including any information included or incorporated by reference in this announcement, is for information purposes only and shall not constitute nor form part of, and should not be construed as, an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. No public offering of the securities referred to in this announcement is being made in the United States or elsewhere.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

Admission to the London Stock Exchange AIM market and Shares Outstanding After Completion

Application will be made for the Shares to be admitted to the AIM market operated by the London Stock Exchange (“Admission”). It is expected that Admission will become effective at 8:00 a.m. GMT on November 26, 2020.

Following admission of the Shares to trading on AIM, the issued share capital of Chi-Med will consist of 727,702,215 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. The figure of 727,702,215 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

For illustrative purposes only, if the 727,702,215 ordinary shares were converted in their entirety, they would be equivalent to 145,540,443 Nasdaq-traded ADSs (each equating to five ordinary shares).

About CPP Investments

Canada Pension Plan Investment Board (CPP Investments™) is a professional investment management organization that invests around the world in the best interests of the more than 20 million contributors and beneficiaries of the Canada Pension Plan. In order to build diversified portfolios of assets, investments in public equities, private equities, real estate, infrastructure and fixed income are made by CPP Investments. Headquartered in Toronto, with offices in Hong Kong, London, Luxembourg, Mumbai, New York City, San Francisco, São Paulo and Sydney, CPP Investments is governed and managed independently of the Canada Pension Plan and at arm’s length from governments. At September 30, 2020, the fund totalled C$456.7 billion.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Chi-Med’s current expectations regarding future events, including its expectations regarding the use of proceeds from the transaction as well as Chi-Med’s clinical development and regulatory plans for its drug candidates and Chi-Med’s overall business strategy. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the funding necessary for Chi-Med’s future clinical development plans, enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the timing and ability of Chi-Med to raise additional funding as needed for continued operations, and the impact of the COVID-19 pandemic on general economic, regulatory and political conditions. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas – Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe – Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
Chi-Med@fticonsulting.com
Asia – Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500

 

Source:- GlobeNewswire

Source link

Continue Reading

Investment

This Is Where Healthcare Leaders Are Investing Their Money – Forbes

Published

 on


2020 has certainly highlighted the value that a strong healthcare system can provide for a community. Moreover, due to the Covid-19 pandemic, healthcare systems and patients worldwide have turned to more creative solutions in order to deal with crises, deliver care when needed, and innovate as necessary.

Throughout this time, funding and investment in the healthcare industry has by no means slowed down. In fact, the need for innovation in a coronavirus pandemic-driven, socially isolated world has provided even more inspiration for investors to put their money into avenues which can provide viable solutions.

Famed consulting firm PricewaterhouseCoopers and CB Insights recently published a report highlighting the latest trends in venture capital funding for healthcare related industries. These key findings indicate where investors are focusing the majority of their time and efforts, and hence likely portray where the healthcare industry is moving.

Location

In terms of “dollars raised,” the report indicates that Silicon Valley, New England, North Central, San Diego, and the New York Metros are the top 5 regions for healthcare. In Q3 of 2020, Silicon Valley raised nearly $2.5 billion, with New England raising $1.9 billion. But this statistic is not entirely surprising, given the sheer amount of capital and technology talent that’s present in the Silicon Valley area. As some of the world’s largest technology companies are so heavily invested in healthcare, this makes sense. Furthermore, Silicon Valley has always been a “startup” hub, with executives easily transferring their talents from one firm to another, seeking to develop the next innovation. New England is no different, given that it is home to some of the largest pharmaceutical and biomedical innovation companies in the world.

Sectors

On a similar note, biotechnology is the leading subsector in healthcare investments. In Q3, investors poured nearly $3.9 billion into this subsector, marking an astounding 38% increase from Q2 2020, which raised $2.8 billion. The push for new innovation in biotechnology has never been more prevalent—ranging from new ways to develop and test treatments, to novel technological tools and interfaces for healthcare. The second heaviest area of investment was medical devices and equipment, with nearly $892 million raised.

Deals

The largest healthcare deals in Q3 2020 were the following:

a.    Bright Health—Value of Deal: $500 Million

b.    Tizona Therapeutics—Value of Deal: $300 Million

c.    Village MD—Value of Deal: $275 Million

d.    Freenome—Value of Deal: $270 Million

e.    Thrive Earlier Detection—Value of Deal: $257 Million

f.     Recursion Pharmaceuticals—Value of Deal: $239 Million

g.    Instil Bio—Value of Deal: $170 Million

h.    Kronos Bio—Value of Deal: $148 Million

The last three of these, Recursion Pharmaceuticals, Instil Bio, and Kronos Bio are all listed as biotechnology companies, yet again driving the point that biotechnology leads the healthcare investments realm.

Overall, this report provides a very pragmatic yet illuminating picture of where investors are placing their money and time. Indeed, 2020 has truly ignited a fire in many to continue to innovate to solve some of healthcare’s toughest challenges. However, given the cyclical nature of healthcare, and the fact that new technology continues to drive forward medical innovation as quickly as it can get developed, these trends are by no means stagnant. Rather, as with any legitimate industry that fosters growth, healthcare will inevitably continue to undergo dynamic transformation in the coming decades.

Let’s block ads! (Why?)



Source link

Continue Reading

Investment

Verv: "Applying for a new investment was tough" – Innovation Origins

Published

 on


When the UK went into lockdown in mid-March, the small Verv team, surprising as it may sound, was well prepared for the turbulent time ahead of them. “In 2019, we had already made significant cost savings after reviewing our business strategy,” says Louanne Steyn, CFO of Verv, “so we had a good overview of all our costs. We knew what we could do to reduce them in the short term.”

For example, Verv canceled the lease of their London office. “We are a small team and now we all work from home. If necessary, we can rent a space to get together.”

Steyn herself works from Devon, southwest of London. “During this pandemic, it is important to cut costs wherever possible and to be intelligent with spending. This will make a difference later on.”

Better focus on product strategy

Verv already had plans to invest in 2020. At the same time, the start-up focused on the latest predictive maintenance technology currently being applied to household appliances such as washing machines, dishwashers and refrigerators. Verv’s technology measures and analyzes the energy consumption of appliances at very high speeds. By applying specialized algorithms to this data, it is able to detect behavioral anomalies that can signal a fault in the machinery. Due to the high resolution of the technology, errors can be detected and prevented in real time, right down to the level of parts of a device.

Integrated microchip

The solution is available in multiple forms, including built-in firmware on an integrated microchip and an online adapter. By remotely performing a thorough analysis, Verv can provide the manufacturer with a detailed diagnosis and recommendations that can be passed on to repair departments and engineers at the companies involved as well as to consumers who own the device.

With sustainability at its core, Verv wants to offer the market more opportunities to repair rather than replace so that devices and appliances last longer and result in less waste. Steyn thinks that the corona crisis may create new opportunities in the market. “People have less money to spend. They want their things to last longer. Maybe now they’ll start thinking more carefully about the use of raw materials.”

Technology for all electrical products

Manufacturers can integrate the microchip into their devices or devices. But owners of existing devices can also benefit from the predictive maintenance solution. The concept is simple: It uses an online adapter with technology to collect the required data and send it to the platform.

The technology can be applied to any electronic device. “Think of chargers for electric cars where it is important to be able to quickly detect anomalies,” says Steyn. This market is expected to grow due to the need for sustainable transportation.

At one point, Verv was looking for new investments to further develop the technology and prepare for a commercial rollout. “This was a lot harder because investors were first looking at their existing portfolios and were reluctant to invest in new start-ups.”

Re-screened by InnoEnergy

In March, one of the owners of Verv, EIT InnoEnergy, investigated the possibility of reinvesting in some of the start-ups it has in its portfolio. “The process of applying for this was very tough,” says Steyn looking back. “We already knew in 2019 that 2020 would be a challenging year. But corona made that even more difficult.”

Verv further increased its focus on business strategy and product development. At the same time, the company went through the selection procedure set up by the EIT InnoEnergy start-up team. “Now that they have made additional investments, we are in a position to much more easily attract other investors.”

Product delivery likely in 2022

Steyn is happy that Verv is experiencing good traction this year and expects the company to survive the corona crisis. “I have worked for other companies within the circular economy before. I think it’s important to contribute to a more sustainable world with Verv.”

Verv’s business objectives and business strategy will not be greatly influenced by corona, Steyn thinks. Its technology remains on track for mass production, which is likely to start in 2022.

Let’s block ads! (Why?)



Source link

Continue Reading

Investment

Almost £10m has been lost to investment scams since March lockdown – Yahoo Canada Sports

Published

 on


The Canadian Press

Montreal Impact use options on 10 players, including striker Quioto, ‘keeper Diop

MONTREAL — The Montreal Impact have elected to hang on to some of the club’s top talent, including striker Romell Quioto and goalkeeper Clement Diop, but may soon be parting ways with midfielder Bojan Krkic. The club announced Friday that it has exercised options for 10 players on its roster and opted not to pick up options for another four. Deals on five other players are set to expire at the end of 2020.“All of these decisions are about the financial and sporting sides, and we need to be better,” Impact sporting director Olivier Renard said on a video call. “We need to make the jump.”Some of the options weren’t picked because the club is looking to make space for new players, he added.“We have space to make movement and we will make that as soon as possible,” Renard said.In addition to Quioto and Diop, Montreal is keeping goalies James Pantemis and Jonathan Sirois, defender Karifa Yao, midfielders Clement Bayiha, Mathiew Choiniere, Tomas Giraldo and Amar Sejdic, and forward Mason Toye. The club previously extended loans for defender Luis Binks and midfielder Lassi Lappalainen through 2021.The club did not exercise options on four players, including Krkic, midfielders Steeven Saba and Shamit Shome, and forward Anthony Jackson-Hamel. The decision doesn’t necessarily mean Krkic won’t wear an Impact jersey next season, however. Renard said the club is interested in bringing the 30-year-old Spanish midfielder back, but decided not to pick up his option “for many reasons.” He said the Impact have made Krkic an offer, and the decision is now up to him.Krkic played in 17 regular-season games for Montreal this year, tallying four goals and two assists.Four other players will be out of contract at the end of December, including defenders Rod Fanni, Jukka Raitala and Jorge Corrales. A loan agreement for midfielder Orji Okwonkwo is also set to expire at the end of the year.Raitala, Montreal’s captain, and Corrales will not return next season, Renard confirmed, but the club is still waiting to see if Fanni, 38, wants to continue playing professionally. The moves come after the Impact finished ninth in Major League Soccer’s Eastern Conference (8-13-2). Montreal was eliminated from the post-season with a 2-1 loss to the New England Revolution in the play-in round. The Impact still have at least one game to play in 2020. The team is set to face Honduran club Olimpia in CONCACAF Champions League action on Dec. 15. Players who did not have their options picked up are not required by MLS to play in the game, but Renard said he is hopeful they will join anyway. This report by The Canadian Press was first published Nov. 27, 2020. The Canadian Press

Let’s block ads! (Why?)



Source link

Continue Reading

Trending